Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eftilagimod alpha - Immutep Limited

Drug Profile

Eftilagimod alpha - Immutep Limited

Alternative Names: EDP-202; Efti; EOC-202; hLAG-3Ig; ImmuFact IMP321; ImmuFact-IMP321; IMP-321; LAG-3-Ig-fusion-protein; LAG-3Ig; sLAG-3-Ig

Latest Information Update: 18 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immutep
  • Developer EOC Pharma; Immutep; Immutep Limited; Krankenhaus Nordwest; Merck & Co; Prima BioMed
  • Class Adjuvants; Antineoplastics; CD antigens; Immunoglobulins; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antigen presenting cell stimulants; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Squamous cell cancer
  • Phase I Malignant melanoma; Solid tumours
  • No development reported Renal cell carcinoma

Most Recent Events

  • 15 Oct 2019 Final efficacy data from a phase I trial in Malignant melanoma released by Immutep (NCT02676869)
  • 26 Sep 2019 Interim efficacy data from the phase II TACTI-002 trial in Non-small cell lung cancer released by Immutep
  • 23 Aug 2019 Immutep has patent protection for Eftilagimod alpha in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top